AI Summary

An international Phase III trial (INTerpath‑001) tested intismeran, a personalized therapeutic cancer vaccine derived from each patient’s tumor, combined with pembrolizumab immunotherapy after surgery for high‑risk melanoma. The regimen cut the risk of cancer recurrence or death by 42% compared with standard treatment. Results were presented by Professor Georgina Long, medical director of the Melanoma Institute Australia and chair of melanoma medical oncology at the University of Sydney, at the European Society for Medical Oncology Congress in 2026.

AI summaries can be wrong sometimes—always verify important details using the source article.